LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

Dynatronics Announces New Credit Facility

August 04, 2023 | Last Trade: US$0.10 0.006 -5.66

Eagan, Minnesota--(Newsfile Corp. - August 4, 2023) - Dynatronics Corporation (NASDAQ: DYNT) ("Dynatronics" or the "Company"), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that on August 1, 2023 the Company and its subsidiaries entered into a new Loan and Security Agreement ("the credit facility") with Gibraltar Business Capital, LLC ("Gibraltar").

Brian Baker, President and Chief Operating Officer, commented, "Over the past few years, Dynatronics has made substantial progress to optimize its cost structure and strengthen its balance sheet. With a solid foundation now in place, the closing of this credit facility provides operational and financial flexibility as we execute our operational plans in today's market conditions."

John Krier, Chief Executive Officer and Chief Financial Officer, commented, "I am pleased we have executed this new credit facility, improved our access to capital through this relationship with Gibraltar, and are poised to be opportunistic to future opportunities."

Dynatronics anticipates it will use the proceeds from the new credit facility to fund its working capital needs and for other general corporate purposes. Additional details on the new credit facility are outlined in the Company's Current Report on Form 8-K filed today with the Securities and Exchange Commission.

About Dynatronics Corporation

Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.

About Gibraltar Business Capital

Chicago-based Gibraltar Business Capital is a well-capitalized, specialty finance company delivering working capital in the form of asset-based loans from $5 to $100 million. Gibraltar is an expert financial partner providing mid-market companies nationwide access to capital when they need it most to solve challenges or fuel growth at any stage of the business lifecycle. With more than 70 years of experience, Gibraltar's team is trained to listen, think differently, and take unique circumstances into account. Gibraltar Business Capital is a portfolio company of multi-billion-dollar specialty finance company Hercules Capital, Inc. (NYSE: HTGC). For more information, visit www.gibraltarbc.com.

Contact:

Dynatronics Corporation
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

For additional information, please visit: www.dynatronics.com.

Connect with Dynatronics on LinkedIn.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page